Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-018-24275-5
Title: Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
Authors: Li, F.-F
Zhang, W.-L
Liu, B.-L
Zhang, D.-F
Chen, W
Yuan, L
Chen, M.-Y
Zhai, X.-F
Wu, J.-D
Su, X.-F
Ye, L 
Cao, H.-Y
Ma, J.-H
Keywords: antidiabetic agent
insulin
insulin glargine
aged
blood
blood glucose monitoring
controlled study
drug administration
female
glucose blood level
human
male
metabolism
middle aged
non insulin dependent diabetes mellitus
outpatient
parenteral nutrition
pathophysiology
randomized controlled trial
retrospective study
subcutaneous drug administration
Aged
Blood Glucose
Blood Glucose Self-Monitoring
Diabetes Mellitus, Type 2
Drug Administration Schedule
Female
Humans
Hypoglycemic Agents
Injections, Subcutaneous
Insulin
Insulin Glargine
Male
Middle Aged
Outpatients
Parenteral Nutrition
Retrospective Studies
Issue Date: 2018
Citation: Li, F.-F, Zhang, W.-L, Liu, B.-L, Zhang, D.-F, Chen, W, Yuan, L, Chen, M.-Y, Zhai, X.-F, Wu, J.-D, Su, X.-F, Ye, L, Cao, H.-Y, Ma, J.-H (2018). Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy. Scientific Reports 8 (1) : 5888. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-018-24275-5
Rights: Attribution 4.0 International
Abstract: To compare the continuous subcutaneous insulin infusion (CSII) or insulin glargine based multiple injections (MDI) therapy on glycemic variations in diabetic patients receiving PN outside of intensive care settings. This was a single-center, randomized, open-label trial. Patients with type 2 diabetes (T2D) who were receiving parenteral nutrition (PN) were recruited. After baseline data were collected, recruited patients were then randomized 1:1 to a CSII group or a MDI group. All patients were subjected to a 4-day retrospective Continuous Glucose Monitoring (CGM). The primary endpoint was the differences of the 24-hrs mean amplitude of glycemic excursion (MAGE) in patients receiving the PN therapy between the two groups. A total of 102 patients with T2D receiving PN were recruited. Patients in the CSII group had a significantly decreased mean glucose level (MBG), the standard deviation of MG (SDBG), MAGE, and the coefficient of variation (CV%) compared to those in MDI group (all P < 0.01). Furthermore, we found that the patients who received a bolus insulin dose required maintaining euglycemic control was gradually decreased during the PN period in both groups at the endpoint. The administration of insulin via CSII led to a significant decrease in glycemic variations in patients receiving PN. © 2018 The Author(s).
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/177821
ISSN: 20452322
DOI: 10.1038/s41598-018-24275-5
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-018-24275-5.pdf1.32 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

6
checked on Nov 27, 2020

Page view(s)

18
checked on Nov 26, 2020

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons